{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T06:02:31Z","timestamp":1794204151287,"version":"4.8.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,23]]},"DOI":"10.7759\/cureus.88601","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T16:23:28Z","timestamp":1753287808000},"source":"Crossref","is-referenced-by-count":5,"title":["Dermatomyositis: A Narrative Review of Skin as a Window to Muscle and Malignancy"],"prefix":"10.7759","author":[{"given":"Maria","family":"Cristofori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 C","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel E","family":"Cort\u00e9s - Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adipp","family":"Sall\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14267","article-title":"Update on dermatomyositis in adults","volume":"18","author":"Schlecht N","year":"2020","unstructured":"Schlecht N, Sunderk\u00f6tter C, Niehaus S, Nashan D. Update on dermatomyositis in adults. J Dtsch Dermatol Ges. 2020, 18:995-1013. 10.1111\/ddg.14267","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.52403\/ijshr.20230407","article-title":"Dermatomyositis: a review of diagnosis and classification criteria","volume":"8","author":"Putri WJ","year":"2023","unstructured":"Putri WJ. Dermatomyositis: a review of diagnosis and classification criteria. Int J Sci Healthcare Res. 2023, 8:42-8. 10.52403\/ijshr.20230407","journal-title":"Int J Sci Healthcare Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1467257","article-title":"Current diagnosis and treatment of polymyositis and dermatomyositis","volume":"28","author":"Sasaki H","year":"2018","unstructured":"Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol. 2018, 28:913-21. 10.1080\/14397595.2018.1467257","journal-title":"Mod Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17536","article-title":"The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of\u00a0existing criteria","volume":"180","author":"Concha JS","year":"2019","unstructured":"Concha JS, Tarazi M, Kushner CJ, Gaffney RG, Werth VP. The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of\u00a0existing criteria. Br J Dermatol. 2019, 180:1001-8. 10.1111\/bjd.17536","journal-title":"Br J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMicm2033425","article-title":"Dermatomyositis","volume":"384","author":"O'Connell KA","year":"2021","unstructured":"O'Connell KA, LaChance AH. Dermatomyositis. N Engl J Med. 2021, 384:2437. 10.1056\/NEJMicm2033425","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2022.01.016","article-title":"Paraneoplastic dermatomyositis","volume":"135","author":"Orton C","year":"2022","unstructured":"Orton C, Topham C, Madigan LM. Paraneoplastic dermatomyositis. Am J Med. 2022, 135:969-71. 10.1016\/j.amjmed.2022.01.016","journal-title":"Am J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094128","article-title":"Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis","volume":"9","author":"Lu X","year":"2014","unstructured":"Lu X, Yang H, Shu X, et al.. Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One. 2014, 9:e94128. 10.1371\/journal.pone.0094128","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01045-w","article-title":"International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies\u00a0Group (IMACS)\u00a0initiative","volume":"19","author":"Oldroyd AG","year":"2023","unstructured":"Oldroyd AG, Callen JP, Chinoy H, et al.. International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies\u00a0Group (IMACS)\u00a0initiative. Nat Rev Rheumatol. 2023, 19:805-17. 10.1038\/s41584-023-01045-w","journal-title":"Nat Rev Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/dh5o6c","article-title":"Idiopathic inflammatory myopathies: one year in review 2023","volume":"42","author":"Conticini E","year":"2024","unstructured":"Conticini E, Dourado E, Bottazzi F, et al.. Idiopathic inflammatory myopathies: one year in review 2023. Clin Exp Rheumatol. 2024, 42:213-24. 10.55563\/clinexprheumatol\/dh5o6c","journal-title":"Clin Exp Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181ca14ff","article-title":"Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy","volume":"89","author":"Trallero-Aragu\u00e1s E","year":"2010","unstructured":"Trallero-Aragu\u00e1s E, Labrador-Horrillo M, Selva-O'Callaghan A, et al.. Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore). 2010, 89:47-52. 10.1097\/MD.0b013e3181ca14ff","journal-title":"Medicine (Baltimore)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas MC","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015, 372:1734-47. 10.1056\/NEJMra1402225","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg IE","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, et al.. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021, 7:86. 10.1038\/s41572-021-00321-x","journal-title":"Nat Rev Dis Primers"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3233\/JND-230168","article-title":"Contribution of complement, microangiopathy and inflammation in idiopathic inflammatory myopathies","volume":"11","author":"Honda M","year":"2024","unstructured":"Honda M, Shimizu F, Sato R, Nakamori M. Contribution of complement, microangiopathy and inflammation in idiopathic inflammatory myopathies. J Neuromuscul Dis. 2024, 11:5-16. 10.3233\/JND-230168","journal-title":"J Neuromuscul Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217240","article-title":"Single-cell profiling of muscle-infiltrating T cells in idiopathic inflammatory myopathies","volume":"15","author":"Argyriou A","year":"2023","unstructured":"Argyriou A, Horuluoglu B, Galindo-Feria AS, et al.. Single-cell profiling of muscle-infiltrating T cells in idiopathic inflammatory myopathies. EMBO Mol Med. 2023, 15:e17240. 10.15252\/emmm.202217240","journal-title":"EMBO Mol Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084301","article-title":"Pathophysiological mechanisms and treatment of dermatomyositis and immune mediated necrotizing myopathies: a focused review","volume":"23","author":"Kamperman RG","year":"2022","unstructured":"Kamperman RG, van der Kooi AJ, de Visser M, Aronica E, Raaphorst J. Pathophysiological mechanisms and treatment of dermatomyositis and immune mediated necrotizing myopathies: a focused review. Int J Mol Sci. 2022, 23:10.3390\/ijms23084301","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh RJ","year":"2007","unstructured":"Walsh RJ, Kong SW, Yao Y, et al.. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007, 56:3784-92. 10.1002\/art.22928","journal-title":"Arthritis Rheum"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.8215","article-title":"Dermatomyositis with positive anti-TIF1 gamma antibodies in an adult female: a case report","volume":"11","author":"Adhikari K","year":"2023","unstructured":"Adhikari K, Pant P, Bhandari S, et al.. Dermatomyositis with positive anti-TIF1 gamma antibodies in an adult female: a case report. Clin Case Rep. 2023, 11:e8215. 10.1002\/ccr3.8215","journal-title":"Clin Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08922-4","article-title":"Autoantibody markers of increased risk of malignancy in patients with dermatomyositis","volume":"63","author":"Marz\u0119cka M","year":"2022","unstructured":"Marz\u0119cka M, Niemczyk A, Rudnicka L. Autoantibody markers of increased risk of malignancy in patients with dermatomyositis. Clin Rev Allergy Immunol. 2022, 63:289-96. 10.1007\/s12016-022-08922-4","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1503140","article-title":"Risk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives","volume":"15","author":"Liu S","year":"2025","unstructured":"Liu S, Zhang Z, Yan S, et al.. Risk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives. Front Oncol. 2025, 15:1503140. 10.3389\/fonc.2025.1503140","journal-title":"Front Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23188","article-title":"Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients","volume":"69","author":"Albayda J","year":"2017","unstructured":"Albayda J, Pinal-Fernandez I, Huang W, et al.. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken). 2017, 69:1771-6. 10.1002\/acr.23188","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/cia2.12048","article-title":"Anti\u2010Mi\u20102 antibody titers and cutaneous manifestations in dermatomyositis","volume":"16","author":"Ogawa\u2010Momohara M","year":"20192025","unstructured":"Ogawa\u2010Momohara M, Muro Y, Akiyama M. Anti\u2010Mi\u20102 antibody titers and cutaneous manifestations in dermatomyositis. J Cutan Immunol Allergy. 20192025, 16:49-52. 10.1002\/cia2.12048","journal-title":"J Cutan Immunol Allergy"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2005.09.004","article-title":"Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis","volume":"40","author":"Komura K","year":"2005","unstructured":"Komura K, Fujimoto M, Matsushita T, et al.. Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. J Dermatol Sci. 2005, 40:215-7. 10.1016\/j.jdermsci.2005.09.004","journal-title":"J Dermatol Sci"},{"key":"ref23","article-title":"Dermatomiositis anti-MDA5. Revisi\u00f3n de la literatura","volume":"61","author":"Castro-Molina SA","year":"2023","unstructured":"Castro-Molina SA, M\u00e9ndez-Flores S. Dermatomiositis anti-MDA5. Revisi\u00f3n de la literatura. Rev Med Inst Mex Seguro Soc. 2023, 61:99-105.","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead154","article-title":"Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature","volume":"62","author":"Demortier J","year":"2023","unstructured":"Demortier J, Vautier M, Chosidow O, et al.. Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature. Rheumatology (Oxford). 2023, 62:3932-9. 10.1093\/rheumatology\/kead154","journal-title":"Rheumatology (Oxford)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa786","article-title":"Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease","volume":"60","author":"Xu A","year":"2021","unstructured":"Xu A, Ye Y, Fu Q, et al.. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease. Rheumatology (Oxford). 2021, 60:3343-51. 10.1093\/rheumatology\/keaa786","journal-title":"Rheumatology (Oxford)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2013(07)04","article-title":"Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis","volume":"68","author":"Cruellas MG","year":"2013","unstructured":"Cruellas MG, Viana Vdos S, Levy-Neto M, Souza FH, Shinjo SK. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics (Sao Paulo). 2013, 68:909-14. 10.6061\/clinics\/2013(07)04","journal-title":"Clinics (Sao Paulo)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-018-0733-5","article-title":"Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies","volume":"20","author":"Wolstencroft PW","year":"2018","unstructured":"Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018, 20:28. 10.1007\/s11926-018-0733-5","journal-title":"Curr Rheumatol Rep"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-4-322","article-title":"Idiopathic inflammatory myopathies - a guide to subtypes, diagnostic approach and treatment","volume":"17","author":"Oldroyd A","year":"2017","unstructured":"Oldroyd A, Lilleker J, Chinoy H. Idiopathic inflammatory myopathies - a guide to subtypes, diagnostic approach and treatment. Clin Med (Lond). 2017, 17:322-8. 10.7861\/clinmedicine.17-4-322","journal-title":"Clin Med (Lond)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-020-00950-3","article-title":"Impact and management of dysphagia in inflammatory myopathies","volume":"22","author":"Zeng R","year":"2020","unstructured":"Zeng R, Schmidt J. Impact and management of dysphagia in inflammatory myopathies. Curr Rheumatol Rep. 2020, 22:74. 10.1007\/s11926-020-00950-3","journal-title":"Curr Rheumatol Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa739","article-title":"Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis","volume":"60","author":"Fornaro M","year":"2021","unstructured":"Fornaro M, Girolamo F, Cavagna L, et al.. Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis. Rheumatology (Oxford). 2021, 60:2916-26. 10.1093\/rheumatology\/keaa739","journal-title":"Rheumatology (Oxford)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S503928","article-title":"Cardiac involvement in idiopathic inflammatory myopathies","volume":"18","author":"Zhu H","year":"2025","unstructured":"Zhu H, Li R, Tan H, et al.. Cardiac involvement in idiopathic inflammatory myopathies. J Inflamm Res. 2025, 18:3879-88. 10.2147\/JIR.S503928","journal-title":"J Inflamm Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003901","article-title":"Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody","volume":"10","author":"Fu Y","year":"2024","unstructured":"Fu Y, Gu L, Chen J, et al.. Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody. RMD Open. 2024, 10:10.1136\/rmdopen-2023-003901","journal-title":"RMD Open"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-019-0864-3","article-title":"PET scan: nuclear medicine imaging in myositis","volume":"21","author":"Selva-O'Callaghan A","year":"2019","unstructured":"Selva-O'Callaghan A, Gil-Vila A, Sim\u00f3-Perdig\u00f3 M, Trallero-Aragu\u00e1s E, Alvarado-C\u00e1rdenas M, Pinal-Fernandez I. PET scan: nuclear medicine imaging in myositis. Curr Rheumatol Rep. 2019, 21:64. 10.1007\/s11926-019-0864-3","journal-title":"Curr Rheumatol Rep"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg IE","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, et al.. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017, 76:1955-64. 10.1136\/annrheumdis-2017-211468","journal-title":"Ann Rheum Dis"},{"key":"ref35","article-title":"The role of imaging in evaluating patients with idiopathic inflammatory myopathies","volume":"114","author":"Kub\u00ednov\u00e1 K","year":"2018","unstructured":"Kub\u00ednov\u00e1 K, Dejthevaporn R, Mann H, Machado PM, Vencovsk\u00fd J. The role of imaging in evaluating patients with idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2018, 114:74-81.","journal-title":"Clin Exp Rheumatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2024.07.005","article-title":"Imaging modalities in myositis: a clinical review","volume":"50","author":"Yoshida T","year":"2024","unstructured":"Yoshida T, Albayda J. Imaging modalities in myositis: a clinical review. Rheum Dis Clin North Am. 2024, 50:641-59. 10.1016\/j.rdc.2024.07.005","journal-title":"Rheum Dis Clin North Am"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101849","article-title":"Nailfold capillaroscopy","volume":"37","author":"Smith V","year":"2023","unstructured":"Smith V, Ickinger C, Hysa E, Snow M, Frech T, Sulli A, Cutolo M. Nailfold capillaroscopy. Best Pract Res Clin Rheumatol. 2023, 37:101849. 10.1016\/j.berh.2023.101849","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd AG","year":"2022","unstructured":"Oldroyd AG, Lilleker JB, Amin T, et al.. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology (Oxford). 2022, 61:1760-8. 10.1093\/rheumatology\/keac115","journal-title":"Rheumatology (Oxford)"},{"key":"ref39","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik JJ","year":"2023","unstructured":"Paik JJ, Lubin G, Gromatzky A, Mudd PN Jr, Ponda MP, Christopher-Stine L. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review. Clin Exp Rheumatol. 2023, 41:348-58.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/391142-dermatomyositis-a-narrative-review-of-skin-as-a-window-to-muscle-and-malignancy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T16:23:29Z","timestamp":1753287809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/391142-dermatomyositis-a-narrative-review-of-skin-as-a-window-to-muscle-and-malignancy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.88601","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,23]]}}}